

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-199

APPROVAL LETTER

NDA 21-199

AUG 18 2000

Santen, Incorporated
Attention: Margaret Reents Timms
Vice President, Regulatory Affairs
555 Gateway Drive
Napa, California 94558

Dear Ms. Timms:

Please refer to your new drug application (NDA) dated February 28, 2000, received March 1, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Quixin (levofloxacin ophthalmic solution) Sterile Ophthalmic Solution 0.5%.

We acknowledge receipt of your submissions dated April 12 and 21, May 12, 17, 18, 19, and 31, June 9, 12, 21, and 22, and August 4 and 15, 2000.

This new drug application provides for the use of Quixin (levofloxacin ophthalmic solution) Sterile Ophthalmic Solution 0.5% for the treatment of bacterial conjunctivitis.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft labeling of the submitted package insert August 15, 2000. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-199." Approval of this submission by FDA is not required before the labeling is used.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 FR 66632). We note that you have fulfilled the pediatric study requirement at this time. We are waiving the pediatric study requirement for pediatric patients below one year of age for this action on this application.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

/s/

Wiley A. Chambers, M.D.
Deputy Director
Division of Anti-Inflammatory, Analgesic and
Ophthalmic Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research